Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Research and Markets - Frontier Pharma Report: Head and Neck Cancer Market 2017 - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

This image opens in the lightbox

News provided by

Research and Markets

07 Apr, 2017, 20:30 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, April 7, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation" drug pipelines to their offering.

The HNC deals landscape is highly active, with a mean value for co-development deals of $496.6m between 2006 and 2016, which is above the 2015 industry average of $346.8m, and a mean value for licensing deals of $198.6m, which is also above the industry average of $198.6m.

Most deals involved drugs with established targets. However, some deals contained a variety of first-in-class products - although deal values were not always disclosed. Despite the risk that can be associated with first-in-class products, they have still been shown to be a highly desirable investment option. Risks are posed through identifying a new target, developing a therapeutic compound for that target and validating the target mechanism for disease intervention in HNC.

The HNC pipeline has 340 products active across all stages of development. The range of mechanisms of action employed by these compounds is very diverse, especially in comparison with the existing market landscape, and matches the diversity of many of the other oncology indication pipelines. More pertinently, there is a large proportion of breakthrough innovation in this pipeline.

Despite risks associated with developing first-in-class products, they have still proven to be a highly desirable investment option. Indeed, the high level of deal-making activity within the head and neck cancer space is indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations to mitigate some of the risks associated with drug development, such as the high attrition rates exhibited by oncology indications.

Factors driving the pipeline size include the limited efficacy of current treatments for refractory patients and a lack of approved targeted therapies in the market landscape, facilitating the development of novel compounds. These factors have far-reaching strategic implications for all market participants, as it is likely that numerous first-in-class products, many of which are supported by promising preclinical data, will reach the market over the coming decade, potentially transforming the clinical and commercial landscape.

Key Topics Covered:

1 Executive Summary
1.1 High Unmet Need and Limited but Expanding Number of Marketed Options
1.2 Large but Highly Innovative Pipeline
1.3 Lucrative Deals Landscape, Mostly Involving Currently Established Targets

2 The Case for Innovation in the Head and Neck Cancer Market
2.1 Growing Opportunities for Biologic Products
2.2 Diversification of Molecular Targets
2.3 Innovative First-in-Class Product Developments Remain Attractive
2.4 Sustained Innovation
2.5 Report Guidance

3 Clinical and Commercial Landscape
3.1 Disease Overview
3.2 Disease Symptoms
3.3 Diagnosis
3.4 Etiology
3.5 Pathophysiology
3.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival
3.5.2 Tumor Metabolic Shift
3.5.3 Tumor Progression, Micro-environment Alteration, Angiogenesis and Metastasis
3.5.4 Cancer Stem Cells
3.6 Epidemiology
3.7 Prognosis
3.8 Head and Neck Cancer Treatment
3.8.1 Surgery and Radiation Therapy
3.8.2 Overview of Marketed Products for Head and Neck Cancer
3.8.3 Current Unmet Need in the Head and Neck Cancer Market

4 Assessment of Pipeline Product Innovation
4.1 Head and Neck Cancer Pipeline by Phase, Molecule Type and Molecular Target
4.2 First-in-Class Pipeline Programs

5 Signaling Network, Disease Causation and Innovation Alignment
5.1 The Complexity of Signaling Networks in Oncology
5.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
5.3 First-in-Class Target Matrix Assessment

6 First-in-Class Target Evaluation
6.1 Pipeline Programs Targeting PIK3CA, PIK3CB and PIK3CG
6.2 Pipeline Programs Targeting HER3
6.3 Pipeline Programs Targeting ADAM17
6.4 Pipeline Programs Targeting Protein Kinase C Epsilon Type
6.5 Pipeline Programs Targeting AKT1, AKT2 and AKT3
6.6 Pipeline Programs Targeting HSP90AA1
6.7 Pipeline Programs Targeting Tyrosine-Protein Kinase SYK
6.8 Pipeline Programs Targeting Telomerase Reverse Transcriptase
6.9 Pipeline Programs Targeting Growth Factor Receptor-Bound Protein 2
6.10 Pipeline Programs Targeting Focal Adhesion Kinase
6.11 Conclusion

7 Deals and Strategic Consolidations
7.1 Industry-Wide First-in-Class Deals
7.2 Head and Neck Cancer Deals Landscape
7.3 Licensing Deals
7.3.1 Molecule Type
7.3.2 Molecular Target
7.4 Co-development Deals
7.4.1 Molecule Type
7.4.2 Molecular Target
7.5 List of Pipeline Products without Prior Licensing or Co-development Deal Involvement

8 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/xch2vk/frontier_pharma

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.